Cargando…
Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. The biological mechanisms underlying cognitive impairment in LLD are complex and likely involve abnormalities in multiple pathways, or “cascades,” reflecte...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494754/ https://www.ncbi.nlm.nih.gov/pubmed/25092249 http://dx.doi.org/10.1038/mp.2014.76 |
_version_ | 1782380147503005696 |
---|---|
author | Diniz, Breno S. Sibille, Etienne Ding, Ying Tseng, George Aizenstein, Howard Lotrich, Francis Becker, James T. Lopez, Oscar L. Lotze, Michael T. Klunk, William E. Reynolds, Charles F. Butters, Meryl A. |
author_facet | Diniz, Breno S. Sibille, Etienne Ding, Ying Tseng, George Aizenstein, Howard Lotrich, Francis Becker, James T. Lopez, Oscar L. Lotze, Michael T. Klunk, William E. Reynolds, Charles F. Butters, Meryl A. |
author_sort | Diniz, Breno S. |
collection | PubMed |
description | Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. The biological mechanisms underlying cognitive impairment in LLD are complex and likely involve abnormalities in multiple pathways, or “cascades,” reflected in specific biomarkers. Our aim was to evaluate peripheral (blood-based) evidence for biological pathways associated with cognitive impairment in older adults with LLD. To this end, we used a data-driven comprehensive proteomic analysis (multiplex immunoassay including 242 proteins), along with measures of structural brain abnormalities (gray matter atrophy and white matter hyperintensity volume via MRI), and brain amyloid-β (Aβ) deposition (PiB-PET). We analyzed data from 80 older adults with remitted major depression (36 with Mild Cognitive Impairment (LLD+MCI) and 44 with normal cognitive function (LLD+NC)). LLD+MCI was associated with differential expression of 24 proteins (p <0.05 and q-value <0.30) related mainly to the regulation of immune-inflammatory activity, intracellular signaling, cell survival, and protein and lipid homeostasis. Individuals with LLD+MCI also showed greater white matter hyperintensity burden compared with LLD+NC (p=0.015). We observed no differences in gray matter volume or brain Aβ deposition between groups. Machine learning analysis showed that a group of three proteins (Apo AI, IL-12, and stem cell factor) yielded accuracy of 81.3%, sensitivity of 75%, and specificity of 86.4% in discriminating participants with MCI from those with normal cognitive function (with an averaged cross-validation accuracy of 76.3%, sensitivity of 69.4% and specificity of 81.8% with nested cross-validation considering the model selection bias). Cognitive impairment in LLD seems to be related to greater cerebrovascular disease along with abnormalities in immune-inflammatory control, cell survival, intracellular signaling, protein and lipid homeostasis, and clotting processes. These results suggest that individuals with LLD and cognitive impairment may be more vulnerable to accelerated brain aging and shed light on possible mediators of their elevated risk for progression to dementia. |
format | Online Article Text |
id | pubmed-4494754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
record_format | MEDLINE/PubMed |
spelling | pubmed-44947542015-11-01 Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression Diniz, Breno S. Sibille, Etienne Ding, Ying Tseng, George Aizenstein, Howard Lotrich, Francis Becker, James T. Lopez, Oscar L. Lotze, Michael T. Klunk, William E. Reynolds, Charles F. Butters, Meryl A. Mol Psychiatry Article Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. The biological mechanisms underlying cognitive impairment in LLD are complex and likely involve abnormalities in multiple pathways, or “cascades,” reflected in specific biomarkers. Our aim was to evaluate peripheral (blood-based) evidence for biological pathways associated with cognitive impairment in older adults with LLD. To this end, we used a data-driven comprehensive proteomic analysis (multiplex immunoassay including 242 proteins), along with measures of structural brain abnormalities (gray matter atrophy and white matter hyperintensity volume via MRI), and brain amyloid-β (Aβ) deposition (PiB-PET). We analyzed data from 80 older adults with remitted major depression (36 with Mild Cognitive Impairment (LLD+MCI) and 44 with normal cognitive function (LLD+NC)). LLD+MCI was associated with differential expression of 24 proteins (p <0.05 and q-value <0.30) related mainly to the regulation of immune-inflammatory activity, intracellular signaling, cell survival, and protein and lipid homeostasis. Individuals with LLD+MCI also showed greater white matter hyperintensity burden compared with LLD+NC (p=0.015). We observed no differences in gray matter volume or brain Aβ deposition between groups. Machine learning analysis showed that a group of three proteins (Apo AI, IL-12, and stem cell factor) yielded accuracy of 81.3%, sensitivity of 75%, and specificity of 86.4% in discriminating participants with MCI from those with normal cognitive function (with an averaged cross-validation accuracy of 76.3%, sensitivity of 69.4% and specificity of 81.8% with nested cross-validation considering the model selection bias). Cognitive impairment in LLD seems to be related to greater cerebrovascular disease along with abnormalities in immune-inflammatory control, cell survival, intracellular signaling, protein and lipid homeostasis, and clotting processes. These results suggest that individuals with LLD and cognitive impairment may be more vulnerable to accelerated brain aging and shed light on possible mediators of their elevated risk for progression to dementia. 2014-08-05 2015-05 /pmc/articles/PMC4494754/ /pubmed/25092249 http://dx.doi.org/10.1038/mp.2014.76 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Diniz, Breno S. Sibille, Etienne Ding, Ying Tseng, George Aizenstein, Howard Lotrich, Francis Becker, James T. Lopez, Oscar L. Lotze, Michael T. Klunk, William E. Reynolds, Charles F. Butters, Meryl A. Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression |
title | Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression |
title_full | Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression |
title_fullStr | Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression |
title_full_unstemmed | Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression |
title_short | Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression |
title_sort | plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494754/ https://www.ncbi.nlm.nih.gov/pubmed/25092249 http://dx.doi.org/10.1038/mp.2014.76 |
work_keys_str_mv | AT dinizbrenos plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT sibilleetienne plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT dingying plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT tsenggeorge plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT aizensteinhoward plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT lotrichfrancis plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT beckerjamest plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT lopezoscarl plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT lotzemichaelt plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT klunkwilliame plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT reynoldscharlesf plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression AT buttersmeryla plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression |